STATCenter·
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Read at STAT →
Health · 1 sources covering this
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/03b1aa510563d2e2e0dfc7bf387f634c7f184ff5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug"></iframe>
